Invisicare Delivery System to Enhance Medical and Recreational Marijuana Product Lines
LAS VEGAS, NV / ACCESSWIRE / February 21, 2017 / Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI), developers of over 40 topical
prescription (Rx), over-the-counter (OTC) and cosmeceutical products using its patented Invisicare® polymer delivery systems,
announces it has now additionally developed topical and transdermal cannabis products from hemp-derived CBD, with its next
developments to include cannabinoids from marijuana (CBD and THC).
"Our research shows that Invisicare formulations have a much greater release of active ingredients than products in the
marketplace, they resist wash-off and rub-off while still allowing the skin to breathe naturally. In addition to these great
benefits, it is our belief that our 15 plus years of topical product development experience, as well as our 14 technology and
product patents, will stand-out in the cannabis marketplace as there is a great need for a 'science based' product line such as
ours," said Terry Howlett, President of Skinvisible. "In conjunction with our partner CannaSkin, LLC, Skinvisible is seeking
licensees to produce and market our cannabis product line in the 28 states where it has been legalized. We are also extending our
reach to Canada and other approved countries while expanding our product line with an array of unique products."
The cannabis market that Skinvisible has entered is vast and one of the fastest growing markets. There is a growing positive
public opinion regarding the cannabis industry due to the increasing amount of encouraging scientific research proving the benefits
and the increasingly supportive cannabis laws. The legal marijuana industry (medical and recreational) in the USA has reached over
$6 billion in annual sales and is expected to increase to over $20 billion by 2020. In Canada, where the entire country is primed
to add recreational marijuana nationally this year, the market is projected to reach $2.5 billion, with some future estimates at a
staggering $10 to $22 billion annually. Skinvisible is poised to be a part of this expanding market. It is part of the ancillary
cannabis market as Skinvisible does not sell or touch cannabis; it sells its proprietary Invisicare polymers coupled with proven
product formulations and services to its licensees. Skinvisible will help bring science-based, patent protected products into this
emerging industry.
Skinvisible's Invisicare drug delivery technology enhances how ingredients are delivered to the skin and through the skin.
Protected by comprehensive patents, Invisicare is the integral component of every formula developed by Skinvisible, including its
cannabis product line. The Invisicare patents protect all Skinvisible formulations from duplication in the marketplace.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a R&D company that licenses its proprietary formulations made with Invisicare®, its patented
polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare
holds active ingredients on the skin for extended periods of time along with controlling the release of actives.
www.skinvisible.com, www.invisicare.com
Forward-Looking Statements:
This press release contains "forward looking" statements within the meaning of Section 21A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby.
Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially
from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file
with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending
September 30, 2016).
Contact:
Doreen McMorran, Skinvisible Inc. info@skinvisible.com Phone: 702-433-7154
SOURCE: Skinvisible Inc.
